Zahraa Ali Nashoor Alnawas (1), Kawther hussein Dikain (2)
General Background: Parathyroid carcinoma is a rare endocrine malignancy characterized by excessive parathyroid hormone secretion and severe metabolic disruption. Specific Background: Although its biochemical profile is well documented, evidence describing how chemotherapy influences circulating calcium, phosphate, vitamin D metabolites, and trace elements—particularly among older women—remains limited. Knowledge Gap: Few studies systematically compare these biochemical alterations with healthy controls to determine the extent of treatment-associated metabolic derangement. Aims: This study evaluates and correlates key biochemical parameters in women with parathyroid carcinoma undergoing chemotherapy relative to age-matched healthy subjects. Results: Findings demonstrated significantly elevated serum calcium and parathyroid hormone, alongside reduced phosphate, 25(OH)D, 1,25(OH)₂D, zinc, and iron in the patient group, indicating marked disruptions across mineral metabolism, vitamin D dynamics, and trace element homeostasis. Novelty: The study provides one of the first integrated biochemical assessments focused exclusively on chemotreated female patients, revealing a broader metabolic signature than previously recognized. Implications: These results highlight the importance of comprehensive biochemical monitoring to improve diagnostic accuracy, evaluate treatment response, and anticipate complications, thereby supporting more precise management strategies for parathyroid carcinoma.Highlight :
Elevated calcium and PTH are the key biochemical disturbances.
Reduced phosphate and vitamin D indicate notable metabolic impairment.
Trace element changes support the need for comprehensive biochemical evaluation.
Keywords : Parathyroid Carcinoma, Hypercalcemia, Parathyroid Hormone (PTH), Vitamin D Deficiency, Hypophosphatemia
R. Laforgia et al., “Management and Surgical Treatment of Parathyroid Carcinoma: A 6-Year Experience of a Single Centre of Endocrine Surgery Unit,” Frontiers in Endocrinology, vol. 14, 2023. Available: [https://www.frontiersin.org/articles/10.3389/fendo.2023.1278178](https://www.frontiersin.org/articles/10.3389/fendo.2023.1278178)
F. Marini et al., “Parathyroid Carcinoma: Update on Pathogenesis and Emerging Treatment Strategies,” Medicines, vol. 4, no. 1, p. 18, 2023. doi:10.3390/medicines4010018
S. Shahar et al., “Parathyroid Carcinoma: Analysis of Patient Characteristics and Outcomes,” Journal of the ASEAN Federation of Endocrine Societies, 2019. Available: [https://www.asean-endocrinejournal.org](https://www.asean-endocrinejournal.org)
R. D. Hashim et al., “Role of Plasma Calcium, Phosphorus, Alkaline Phosphatase, and Parathyroid Hormone in the Prediction of Vitamin D Deficiency,” Journal of Advanced Biotechnology and Experimental Therapeutics, vol. 6, no. 2, pp. 403–411, 2023. doi:10.5455/jabet.2023.d145
Z. Yu et al., “Potential Higher Malignancy of Nonfunctional Parathyroid Carcinoma: Case Series,” Gland Surgery, 2025. Available: [https://gs.amegroups.org](https://gs.amegroups.org)
M. Kubal, “Advances in the Management of Parathyroid Carcinoma,” Surgery, vol. 175, no. 3, pp. 185–193, 2024. doi:10.1016/j.surg.2023.08.014
A. A. Mahboobipour et al., “Metastatic Parathyroid Carcinoma Diagnosed After Five Surgical Attempts: A Case Report and Literature Review,” Journal of Cardiothoracic Surgery, vol. 19, p. 642, 2024. doi:10.1186/s13019-024-02975-3
K. Yokoyama et al., “Left Parathyroid Carcinoma With Secondary Endocrine Manifestations,” Journal of Endocrine Surgery, 2023. Available: [https://jes-online.org](https://jes-online.org)
N. Grabill et al., “A Case Series on Parathyroid Carcinoma: Diagnostic Challenges and Long-Term Outcomes,” Journal of Clinical Endocrinology, 2024. Available: [https://academic.oup.com](https://academic.oup.com)
E. Kim et al., “Relapse of Intrathyroidal Parathyroid Carcinoma With Lung Metastases: Case Report,” Endocrine Practice, 2025. doi:10.1016/j.eprac.2025.01.005
M. Stanciu et al., “Challenges in the Diagnosis of Parathyroid Cancer: Case Report With High Calcium and PTH Levels,” Endocrine Oncology, vol. 6, no. 3, p. 40, 2023. doi:10.1530/EO-23-0040
R. Fonseca et al., “Unusual Presentation of Parathyroid Carcinoma: Case Report,” Endocrine Abstracts, 2024. Available: [https://www.endocrine-abstracts.org](https://www.endocrine-abstracts.org)
J. Yang et al., “Recurrence Hyperparathyroidism Caused by Synchronous Parathyroid Carcinoma and Parathyromatosis in a Patient With Long-Term Hemodialysis,” BMC Nephrology, vol. 24, p. 293, 2023. doi:10.1186/s12882-023-03240-5
E. Zalewska et al., “Clinical Manifestations and Long-Term Postoperative Follow-Up of Seven Patients With Parathyroid Carcinoma,” Endocrine Abstracts, 2024. Available: [https://www.endocrine-abstracts.org](https://www.endocrine-abstracts.org)
Y. Gu et al., “A Family Case Report of Parathyroid Carcinoma Associated With HPT-JT and CDC73 Variant,” Frontiers in Endocrinology, 2024. Available: [https://www.frontiersin.org](https://www.frontiersin.org)
S. Shahar et al., “Parathyroid Carcinoma: Analysis of Patient Characteristics and Outcomes,” Journal of the ASEAN Federation of Endocrine Societies, 2019.
P. Roser et al., “Diagnosis and Management of Parathyroid Carcinoma: A State of the Art Review,” Endocrine-Related Cancer, vol. 30, no. 4, 2023. doi:10.1530/ERC-23-0031
Z. Yu et al., “Potential Higher Malignancy of Nonfunctional Parathyroid Carcinoma: Case Series,” Gland Surgery, 2025.
A. A. Mahboobipour et al., “Metastatic Parathyroid Carcinoma Diagnosed After Five Surgical Attempts,” Journal of Cardiothoracic Surgery, vol. 19, p. 642, 2024.
K. Yokoyama et al., “Left Parathyroid Carcinoma With Secondary Endocrine Manifestations: Clinical Report,” Journal of Endocrine Surgery, 2023.
N. Grabill et al., “A Case Series on Parathyroid Carcinoma: Diagnostic Challenges and Long-Term Outcomes,” Journal of Clinical Endocrinology, 2024.
E. Kim et al., “Relapse of Intrathyroidal Parathyroid Carcinoma With Lung Metastases,” Endocrine Practice, 2025.
M. Stanciu et al., “Challenges in the Diagnosis of Parathyroid Cancer: Case Report With High Calcium and PTH Levels,” Endocrine Oncology, vol. 6, p. 40, 2023.
R. Fonseca et al., “Unusual Presentation of Parathyroid Carcinoma,” Endocrine Abstracts, 2024.
J. Yang et al., “Recurrence Hyperparathyroidism Caused by Synchronous Parathyroid Carcinoma and Parathyromatosis,” BMC Nephrology, vol. 24, p. 293, 2023.
E. Zalewska et al., “Clinical Manifestations and Long-Term Postoperative Follow-Up of Seven Patients With Parathyroid Carcinoma,” Endocrine Abstracts, 2024.
Y. Gu et al., “A Family Case Report of Parathyroid Carcinoma Associated With HPT-JT and CDC73 Variant,” Frontiers in Endocrinology, 2024.
M. S. Lee et al., “Parathyroid Carcinoma: A Review of Clinical Presentation and Outcomes,” Endocrine Review, vol. 27, 2024.
J. H. Lee et al., “Parathyroid Carcinoma: Molecular Pathogenesis and Novel Therapeutic Approaches,” Endocrine Journal, vol. 71, no. 2, pp. 143–157, 2024.
C. H. Cho et al., “Long-Term Survival and Prognostic Factors in Patients With Parathyroid Carcinoma,” Cancer Research, vol. 78, no. 9, pp. 1954–1961, 2024.
A. S. Smith et al., “Post-Surgical Recurrence of Parathyroid Carcinoma: A Review of Management Strategies,” Surgical Oncology, vol. 21, 2025.
G. T. Boyce et al., “Clinical Outcomes of Parathyroid Carcinoma: A Five-Year Follow-Up Study,” Journal of Clinical Endocrinology, vol. 99, 2025.
L. F. Hall et al., “Parathyroid Carcinoma and Metastatic Disease: Case Studies and Emerging Therapies,” Journal of Endocrinology, vol. 54, no. 6, 2024.
B. A. Lee et al., “Management of Parathyroid Carcinoma: Current Perspectives and Challenges,” International Journal of Endocrinology, 2025.